Today The Zimmer Biomet Holdings, Inc. (ZBH) Position Boosted by Winslow Capital Management LLC

Today The Zimmer Biomet Holdings, Inc. (ZBH) Position Boosted by Winslow Capital Management LLC

Winslow Capital Management LLC boosted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 6.1% during the third quarter, Holdings Channel reports. The institutional investor owned 2,732,842 shares of the company’s stock after buying an additional 157,563 shares during the period. Zimmer Biomet Holdings accounts for about 1.5% of Winslow Capital Management LLC’s investment portfolio, making the stock its 23rd largest position. Winslow Capital Management LLC’s holdings in Zimmer Biomet Holdings were worth $355,324,000 as of its most recent SEC filing.

Other large investors have also recently made changes to their positions in the company. Trillium Asset Management LLC boosted its stake in shares of Zimmer Biomet Holdings by 8.3% in the second quarter. Trillium Asset Management LLC now owns 140,340 shares of the company’s stock valued at $16,894,000 after buying an additional 10,756 shares in the last quarter. Grandfield & Dodd LLC boosted its stake in shares of Zimmer Biomet Holdings by 1.8% in the second quarter. Grandfield & Dodd LLC now owns 88,266 shares of the company’s stock valued at $10,625,000 after buying an additional 1,550 shares in the last quarter. Advisory Services Network LLC boosted its stake in shares of Zimmer Biomet Holdings by 0.6% in the second quarter. Advisory Services Network LLC now owns 2,496 shares of the company’s stock valued at $301,000 after buying an additional 15 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. boosted its stake in shares of Zimmer Biomet Holdings by 21.1% in the second quarter. Tokio Marine Asset Management Co. Ltd. now owns 6,085 shares of the company’s stock valued at $733,000 after buying an additional 1,060 shares in the last quarter. Finally, Ramsay Stattman Vela & Price Inc. boosted its stake in shares of Zimmer Biomet Holdings by 7.9% in the second quarter. Ramsay Stattman Vela & Price Inc. now owns 30,830 shares of the company’s stock valued at $3,711,000 after buying an additional 2,265 shares in the last quarter. Institutional investors and hedge funds own 85.86% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) traded up 0.697% during trading on Wednesday, reaching $115.358. The company’s stock had a trading volume of 280,438 shares. The company has a market capitalization of $23.11 billion, a P/E ratio of 64.590 and a beta of 1.23. Zimmer Biomet Holdings, Inc. has a 12-month low of $88.27 and a 12-month high of $133.21. The firm’s 50-day moving average price is $107.15 and its 200 day moving average price is $117.96.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings data on Monday, October 31st. The company reported $1.79 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.79. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The business had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. During the same quarter in the previous year, the company posted $1.64 EPS. The company’s revenue was up 4.0% compared to the same quarter last year. On average, analysts predict that Zimmer Biomet Holdings, Inc. will post $7.92 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 27th. Shareholders of record on Friday, December 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.84%. The ex-dividend date is Wednesday, December 28th. Zimmer Biomet Holdings’s payout ratio is 75.00%.

ZBH has been the topic of several analyst reports. Royal Bank Of Canada decreased their price target on Zimmer Biomet Holdings from $143.00 to $130.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 1st. Northcoast Research cut Zimmer Biomet Holdings from a “buy” rating to a “neutral” rating in a research report on Tuesday, November 8th. J P Morgan Chase & Co set a $134.00 price target on Zimmer Biomet Holdings and gave the company a “buy” rating in a research report on Thursday, January 5th. Canaccord Genuity reiterated a “buy” rating and set a $130.00 price target (down from $150.00) on shares of Zimmer Biomet Holdings in a research report on Monday, October 31st. Finally, Needham & Company LLC reiterated a “buy” rating and set a $148.00 price target on shares of Zimmer Biomet Holdings in a research report on Thursday, December 15th. Four equities research analysts have rated the stock with a hold rating and twenty have issued a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $130.45.

In other Zimmer Biomet Holdings news, insider David A. Jr. Nolan sold 5,050 shares of Zimmer Biomet Holdings stock in a transaction that occurred on Friday, December 2nd. The stock was sold at an average price of $101.11, for a total value of $510,605.50. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Insiders own 1.22% of the company’s stock.

About Zimmer Biomet Holdings

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Related posts

Leave a Comment